Home LiteratureArticle Details
PMID: 17431762 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases.

Breast cancer research and treatment ·Vol. 107 ·No. 2 ·2008-01-00 ·Pages 249-57

Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG

Abstract

We have previously demonstrated in a pilot study of 348 invasive breast cancers that mast cell (MC) infiltrates within primary breast cancers are associated with a good prognosis. Our aim was to verify this finding in a larger cohort of invasive breast cancer patients and examine the relationship between the presence of MCs and other clinical and pathological features. Clinically annotated tissue microarrays (TMAs) containing 4,444 cases were constructed and stained with c-Kit (CD-117) using standard immunoperoxidase techniques to identify and quantify MCs. For statistical analysis, we applied a split-sample validation technique. Breast cancer specific survival was analyzed by Kaplan-Meier [KM] method and log rank test was used to compare survival curves. Survival analysis by KM method showed that the presence of stromal MCs was a favourable prognostic factor in the training set (P = 0.001), and the validation set group (P = 0.006). X-tile plot generated to define the optimal number of MCs showed that the presence of any number of stromal MCs predicted good prognosis. Multivariate analysis showed that the MC effect in the training set (Hazard ratio [HR] = 0.804, 95% Confidence interval [CI], 0.653-0.991, P = 0.041) and validation set analysis (HR = 0.846, 95% CI, 0.683-1.049, P = 0.128) was independent of age, tumor grade, tumor size, lymph node, ER and Her2 status. This study concludes that stromal MC infiltration in invasive breast cancer is an independent good prognostic marker and reiterates the critical role of local inflammatory responses in breast cancer progression.

MeSH Terms
Adult Aged Aged, 80 and over Breast Neoplasms/diagnosis,pathology,therapy Disease Progression Female Humans Immunohistochemistry Male Mast Cells/cytology,metabolism Middle Aged Pilot Projects Prognosis Proportional Hazards Models Stromal Cells/cytology,metabolism
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Rajput Ashish B
Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada.
Turbin Dmitry A
Cheang Maggie Cu
Voduc David K
Leung Sam
Gelmon Karen A
Gilks C Blake
Huntsman David G
References (42)
42 references, click to expand
  1. Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease.
    Leuk Res. 2002 Jan;26(1):83-90 PMID: 11734306
  2. The role of mast cells in tumour angiogenesis.
    Br J Haematol. 2001 Dec;115(3):514-21 PMID: 11736931
  3. Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy.
    Mod Pathol. 2002 Aug;15(8):831-7 PMID: 12181268
  4. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays.
    Am J Pathol. 2002 Nov;161(5):1557-65 PMID: 12414504
  5. Tumor angiogenesis of non-small cell lung cancer.
    Microsc Res Tech. 2003 Feb 1;60(2):186-98 PMID: 12539173
  6. Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC).
    Lung Cancer. 2004 Jan;43(1):47-54 PMID: 14698536
  7. Mast cell chymase induces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions.
    Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):238-43 PMID: 12588765
  8. Mast cells: the Jekyll and Hyde of tumor growth.
    Trends Immunol. 2004 May;25(5):235-41 PMID: 15099563
  9. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis.
    Mod Pathol. 2004 Jun;17(6):690-5 PMID: 15044916
  10. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  11. Mouse mast cells as anti-tumor effector cells.
    Cell Immunol. 1980 Oct;55(2):294-301 PMID: 7428049
  12. Mast cell-mediated tumor-cell cytotoxicity. Role of the peroxidase system.
    J Exp Med. 1981 Mar 1;153(3):520-33 PMID: 7252407
  13. Inverse correlation between tumor incidence and tissue histamine levels in W/WV, WV/+, and +/+ mice.
    J Natl Cancer Inst. 1985 Mar;74(3):671-4 PMID: 3856069
  14. In vitro generated mast cells express natural cytotoxicity against tumour cells.
    Immunology. 1985 Jun;55(2):317-24 PMID: 3924820
  15. The human neutrophil serine proteinases, elastase and cathepsin G, can mediate glomerular injury in vivo.
    J Exp Med. 1988 Sep 1;168(3):1169-74 PMID: 3049904
  16. Mast cell tryptase is a mitogen for cultured fibroblasts.
    J Clin Invest. 1991 Aug;88(2):493-9 PMID: 1864960
  17. Inhibition of mast cell secretion by oxidation products of natural polyamines.
    Biochem Pharmacol. 1992 May 28;43(10):2237-45 PMID: 1599509
  18. Mast cells in breast cancer.
    Anticancer Res. 1993 May-Jun;13(3):785-8 PMID: 8317912
  19. Mast cells in colorectal neoplasias and premalignant disorders.
    Dis Colon Rectum. 1995 Mar;38(3):290-3 PMID: 7882795
  20. Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix.
    J Cell Biochem. 2001 Aug 1-9;83(2):259-70 PMID: 11573243
  21. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma.
    Eur Respir J. 2000 Jun;15(6):1087-93 PMID: 10885428
  22. Correlation between mast cells and survival rates in patients with pulmonary adenocarcinoma.
    Lung Cancer. 1999 Nov;26(2):103-8 PMID: 10568681
  23. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
    J Clin Oncol. 2006 Dec 20;24(36):5637-44 PMID: 17116944
  24. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
    Science. 2006 Sep 29;313(5795):1960-4 PMID: 17008531
  25. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer.
    J Clin Oncol. 2005 Dec 10;23(35):8959-67 PMID: 16219934
  26. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
    J Clin Invest. 2005 Dec;115(12):3623-33 PMID: 16308572
  27. Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer.
    Gynecol Oncol. 2005 Oct;99(1):20-5 PMID: 16055178
  28. The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2005 Oct;28(4):617-21 PMID: 16125954
  29. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).
    Blood. 2005 Sep 15;106(6):2169-74 PMID: 15933054
  30. Determination of stromal signatures in breast carcinoma.
    PLoS Biol. 2005 Jun;3(6):e187 PMID: 15869330
  31. Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
    J Clin Oncol. 2005 Apr 20;23(12):2716-25 PMID: 15837986
  32. Mast cell-mediated apoptosis of endothelial cells in vitro: a paracrine mechanism involving TNF-alpha-mediated down-regulation of bcl-2 expression.
    J Cell Physiol. 2003 Apr;195(1):130-8 PMID: 12599216
  33. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer.
    World J Gastroenterol. 2005 Feb 28;11(8):1210-4 PMID: 15754407
  34. Tumor-stroma interactions.
    Curr Opin Genet Dev. 2005 Feb;15(1):97-101 PMID: 15661539
  35. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.
    Clin Cancer Res. 2004 Nov 1;10(21):7252-9 PMID: 15534099
  36. Mast cells cause apoptosis of cardiomyocytes and proliferation of other intramyocardial cells in vitro.
    Circulation. 1999 Sep 28;100(13):1443-9 PMID: 10500047
  37. Human mast cell chymase induces the accumulation of neutrophils, eosinophils and other inflammatory cells in vivo.
    Br J Pharmacol. 1998 Dec;125(7):1491-500 PMID: 9884078
  38. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome.
    Am J Pathol. 1998 Jan;152(1):83-92 PMID: 9422526
  39. Expression of stem cell factor in basal cell carcinoma.
    Br J Dermatol. 1997 Nov;137(5):709-13 PMID: 9415229
  40. Tumour-educated macrophages promote tumour progression and metastasis.
    Nat Rev Cancer. 2004 Jan;4(1):71-8 PMID: 14708027
  41. Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase.
    J Biol Chem. 1997 Jan 17;272(3):1849-55 PMID: 8999871
  42. Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions.
    Int J Cancer. 1997 Jul 29;72(3):385-8 PMID: 9247277
Article Info
Journal
Breast cancer research and treatment
Abbr.
Breast Cancer Res Treat
ISSN
1573-7217
Published
2008-01-00
Epub
2007-00-13
Pages
249-57
Language
English
Region
Netherlands
NLM ID
8111104
PMCID
PMC2137942
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com